- Home
- SHLS vs SYRE Comparison
SHLS vs SYRE Comparison
Compare SHLS & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHLS
- SYRE
- Stock Information
- Founded
- SHLS 1996
- SYRE 2013
- Country
- SHLS United States
- SYRE United States
- Employees
- SHLS N/A
- SYRE N/A
- Industry
- SHLS Semiconductors
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SHLS Technology
- SYRE Health Care
- Exchange
- SHLS Nasdaq
- SYRE Nasdaq
- Market Cap
- SHLS 1.1B
- SYRE 1.1B
- IPO Year
- SHLS 2021
- SYRE 2016
- Fundamental
- Price
- SHLS $7.16
- SYRE $17.00
- Analyst Decision
- SHLS Buy
- SYRE Buy
- Analyst Count
- SHLS 21
- SYRE 5
- Target Price
- SHLS $9.51
- SYRE $55.00
- AVG Volume (30 Days)
- SHLS 6.1M
- SYRE 438.9K
- Earning Date
- SHLS 08-05-2025
- SYRE 08-05-2025
- Dividend Yield
- SHLS N/A
- SYRE N/A
- EPS Growth
- SHLS N/A
- SYRE N/A
- EPS
- SHLS 0.12
- SYRE N/A
- Revenue
- SHLS $400,354,000.00
- SYRE N/A
- Revenue This Year
- SHLS $17.70
- SYRE N/A
- Revenue Next Year
- SHLS $13.49
- SYRE N/A
- P/E Ratio
- SHLS $59.98
- SYRE N/A
- Revenue Growth
- SHLS N/A
- SYRE N/A
- 52 Week Low
- SHLS $2.71
- SYRE $10.91
- 52 Week High
- SHLS $7.62
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- SHLS 67.71
- SYRE 53.61
- Support Level
- SHLS $6.62
- SYRE $16.23
- Resistance Level
- SHLS $7.46
- SYRE $17.44
- Average True Range (ATR)
- SHLS 0.51
- SYRE 0.83
- MACD
- SHLS 0.11
- SYRE 0.01
- Stochastic Oscillator
- SHLS 79.05
- SYRE 61.35
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.